Immunological Resolution of Human Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2014..
Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Outcomes After Second Hematopoietic Cell Transplant for Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2018.
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123-3131.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
A Phase 3, Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who Failed to Respond to Steroid Treatment for Acute GVHD. Biol Blood Marrow Transplant. 2020.
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.